Project Grant R43EB023408

Pearl Diagnostics, Inc., a woman-owned small business based in Maryland, received a $999,316 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 24, 2025. The award supports the development and commercialization of a rapid, point-of-care (POC) lateral flow device (LFD) for diagnosing invasive aspergillosis (IA), a fungal infection designated by the World Health Organization...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $238,500 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, San Diego (UCSD) to develop a novel electrochemical lateral flow assay (ELFA) for diagnosing tuberculosis (TB) from a single drop of blood. The objective is to create a highly sensitive and specific point-of-need TB detection test that can accurately distinguish active TB from...

Pace Diagnostics, Inc. received a $600,000 Project Grant from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283), awarded on September 30, 2025, with a completion date of March 31, 2026. The award funds the development of an ultrasensitive urine tuberculosis (TB) antigen rapid detection test designed to diagnose active tuberculosis. This innovative diagnostic technology represents the type of medical advancement supported under CFDA...

Federal Cooperative Agreement Summary Prompt Diagnostics, Inc. received a $1.25M Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded June 15, 2025, with completion targeted for May 31, 2027. The company is developing an automated, multiplexed point-of-care diagnostic platform for rapid detection and quantification of Treponema pallidum infections (syphilis). The solution integrates magnetic...

This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to RT Microdx Inc. provides $274,362 to develop a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-quality accuracy for at-home use by non-healthcare professionals. Key technical objectives include optimizing the sensitivity of the platform's pH-sensitive polymer detection mechanism and ensuring robust performance at...

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 to Resonantia Diagnostics, Inc. to develop a transformative diagnostic platform for rapid identification and antimicrobial susceptibility testing of pathogens. The project aims to achieve three key technical objectives: (1) demonstrate accurate antimicrobial susceptibility testing at very low pathogen loads, (2) validate testing...

The National Science Foundation (NSF) awarded a $550,000 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program to the University of California, Los Angeles (UCLA) to develop a rapid, multiplexed diagnostic tool for serological testing of tick-borne diseases (TBDs). This 2-year project seeks to improve blood-based detection of TBDs, including Lyme disease, Babesia, Anaplasma, and relapsing fever, through an innovative point-of-care (POC) serological assay. The goal is...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $284,517 Project Grant (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Electronic Biosciences, Inc. to develop a point-of-care diagnostic assay for detecting autoantibodies associated with type 1 diabetes (T1D). This project aims to leverage nanopore technology to create a rapid, cost-effective test for screening populations, especially children, for T1D biomarkers that appear...

The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,000,000 Project Grant to Accure Medical Inc. on April 3, 2025. The grant supports the development of the TheraWaveTM 100, a novel, non-invasive treatment for onychomycosis, a debilitating fungal nail infection that affects over 5% of the global population. The project aims to use targeted, controlled high-frequency energy to...